Quantcast

Latest Niemann–Pick disease Stories

2014-09-18 08:29:48

- Dr. Altstiel brings over 30 years of expertise in neurodegenerative diseases - NEWARK, N.J., Sept. 18, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) today announced the appointment of Larry D. Altstiel, M.D., Ph.D. to the Company's Board of Directors, effective September 12, 2014. The appointment of Dr. Altstiel fills a vacancy on the Board of seven members. Dr. Altstiel will also become Chairman of the Nominating and Corporate Governance Committee and a member of the Audit...

2014-07-23 23:18:14

Investment builds company strength in preparation for clinical trials. Alachua, Fla. (PRWEB) July 22, 2014 CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer and distributor of cyclodextrins for the pharmaceutical, medical device, cosmetics, and other markets, announced today that it has closed on a Private Placement with a group of qualified private investors led by Novit L.P., an investment arm of U.S. Pharmacia. The transaction involved the signing of a Securities Purchase Agreement...

2014-07-22 08:32:03

- Neurotrope enters into world-wide, exclusive license agreement with Mount Sinai; Files related provisional patent for Bryostatin-1 - PLANTATION, Fla., July 22, 2014 /PRNewswire/ -- Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. (OTCQB: NTRP) has signed a world-wide, exclusive license agreement with the Icahn School of Medicine at Mount Sinai (Mount Sinai) to utilize its proprietary information and data package for the use of Bryostatin-1 in the treatment of...

2014-07-09 23:04:12

Dr. Jeffrey Tate promoted to CEO; C.E. Rick Strattan to serve as Executive Chairman. Alachua, FL (PRWEB) July 09, 2014 CTD Holdings, Inc. (OTCQB:CTDH), a distributor and manufacturer of cyclodextrin products including the orphan drug designated Trappsol(R) Cyclo(TM), today announced the promotion of Dr. Jeffrey Tate to Chief Executive Officer, following the retirement of C.E. Rick Strattan. Dr. Tate will hold the titles of President and CEO of CTD Holdings, Inc.; Mr. Strattan will become...

2014-06-05 23:14:01

Dr. Jeffrey Tate will chair 2016 event to be held in Gainesville, Fla. Alachua, Fla. (PRWEB) June 05, 2014 CTD Holdings, Inc. (OTCQB: CTDH), a distributor and manufacturer of cyclodextrin products including the orphan drug designated Trappsol(R) Cyclo(TM), today announced that President and Director Dr. Jeffrey Tate has been named Chairman of the 18th International Cyclodextrin Symposium to be held in Gainesville, Fla. in 2016. The Symposium Advisory Board reviewed three proposals to host...

2014-05-22 23:15:27

Newly created Board positions will focus on corporate governance and capital markets programs. Alachua, FL (PRWEB) May 22, 2014 CTD Holdings, Inc., a distributor and manufacturer of cyclodextrin products including the orphan drug designated Trappsol(R) Cyclo(TM), (OTCQB: CTDH) announced that its Board of Directors voted to create the new positions of Vice Chairman and Lead Director. The Board, in the same May 16, 2014, meeting, then appointed N. Scott Fine to fill the new roles based on...

2014-04-16 23:07:54

Investment establishes a strategic relationship with the USP Group for product development and marketing and adds new board member. Alachua, FL (PRWEB) April 16, 2014 CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer and distributor of cyclodextrins for the pharmaceutical, medical device, cosmetics and other markets, announced today that it has closed on a Securities Purchase and Collaboration Agreement with Novit LP an affiliated entity of the USP Group, a major manufacturer and...

2014-02-20 23:32:30

Investment to speed development of orphan drug, other corporate goals. Alachua, FL (PRWEB) February 20, 2014 CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer of cyclodextrins for the pharmaceutical and other markets, announced today that it has closed on a private placement of $500,000 with a group of seasoned international investors who are experienced in the consumer and healthcare industries. The investment is meant to help accelerate the development of the Company’s Trappsol(R)...

2013-07-31 23:26:40

As part of the multi-year agreement Gallus will provide process and method development, scale-up, clinical supply and preparation for commercial manufacturing for an infused protein-based therapy targeting the rare disease, Niemann-Pick type B. St. Louis, Missouri (PRWEB) July 31, 2013 Gallus Biopharmaceuticals, LLC (Gallus) has signed a development and manufacturing supply agreement with Genzyme, a Sanofi Company the pioneer in the development and delivery of transformative therapies for...

2013-07-09 23:02:35

Notre Dame FCU partners with the University of Notre Dame's College of Science to support the Ara Parseghian Medical Research Foundation and sponsorship of the fourth annual Road to Discovery bike ride. Representatives from NDFCU will be active participants in the cross-country Road to Discovery bike ride helping bring awareness and promote fundraising to find treatment and a cure for the rare and deadly disease, Niemann-Pick Type C (NPC). Notre Dame, IN (PRWEB) July 09, 2013 Every...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related